Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer's Disease Model

Area of Science:

• Neuroscience
• Toxicology
• Pharmacology

Background:

• Aluminum exposure is linked to neurodegenerative diseases like Alzheimer's disease (AD).
• Aluminum chloride (AlCl3) is a common inducer of experimental AD models.
• Oxidative stress, inflammation, and neurotransmitter imbalances are key pathological features of AD.

Purpose of the Study:

• To investigate the neuroprotective effects of quercetin nanoemulsion (QCNE) against AlCl3-induced neuronal dysfunction.
• To evaluate the efficacy of QCNE in modulating biochemical and inflammatory markers in an AD model.
• To compare the therapeutic potential of quercetin (QC) and QCNE in mitigating AlCl3 toxicity.

Main Methods:

• Experimental Alzheimer's disease (AD) was induced using aluminum chloride (AlCl3) in animal models.
• Animals were treated with quercetin (QC) or quercetin nanoemulsion (QCNE) via oral or intraperitoneal routes.
• Biochemical analyses included neurotransmitter levels, oxidant/antioxidant parameters, and inflammatory markers.
• Immunohistochemical analysis assessed cyclooxygenase (COX-1 and COX-2) expression in brain tissue.

Main Results:

• AlCl3 exposure significantly increased oxidative stress, inflammation, and altered neurotransmitter levels in the AD group.
• Treatment with QC and QCNE attenuated these detrimental effects, with QCNE showing greater potency.
• QCNE administration led to elevated brain antioxidant and anti-inflammatory activities and normalized neurotransmitter levels.
• Histopathological changes were ameliorated, confirming the neuroprotective role of QCNE.

Conclusions:

• Quercetin nanoemulsion (QCNE) demonstrates significant potential in protecting against aluminum-induced neuronal dysfunction and Alzheimer's-like pathology.
• QCNE effectively mitigates oxidative stress, neuroinflammation, and neurotransmitter imbalances associated with AlCl3 exposure.
• QCNE represents a promising therapeutic strategy for managing neurodegenerative conditions linked to aluminum toxicity.